Expression of long chain noncoding RNA POU6F2-AS2 in human gastric cancer tissues and its clinical significance_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

YAO Lin ¹ , TAN Wang ¹ , YANG Facai ² , XIANG Wanping ¹ ,  XIAO Jiangwei ³

1. Department of Gastrointestinal Surgery, Affiliated Hospital of North Sichuan Medical College; Institute of Hepatobiliary and Pancreatic Diseases, North Sichuan Medical College, Nanchong, Sichuan 637000, P. R. China;
2. Department of Hepatobiliary Surgery, Affiliated Hospital of North Sichuan Medical College; Institute of Hepatobiliary and Pancreatic Diseases, North Sichuan Medical College, Nanchong, Sichuan 637000, P. R. China;
3. Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chengdu Medical College, Chengdu 610050, P. R. China;

Corresponding author：

XIAO Jiangwei, Email: xiaojiangwei@126.com

Keywords：

gastric cancer; long chain noncoding RNA; POU6F2-AS2 gene; prognosis

DOI：

10.7507/1007-9424.201812073

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate expression and clinical significance of long chain noncoding RNA POU6F2-AS2 in human gastric cancer tissues.Methods Seventy-three pairs of human gastric cancer and matched paracancerous tissues from May 2017 to May 2018 in the Affiliated Hospital of North Sichuan Medical College were collected. The real-time fluorescence quantitative polymerase chain reaction was used to detect the expression level of POU6F2-AS2 in the gastric cancer tissue and its paracancerous tissue. The correlations between its expression level and clinicalpathologic features of patients were analyzed by the chi-square text. The relationship between the expression of POU6F2-AS2 and the overall survival rate of patient with gastric cancer was analyzed by the Kaplan Meier Plotter database data.Results The relative expression of POU6F2-AS2 in the gastric cancer tissues was significantly higher than that in the corresponding adjacent tissues (P<0.050). The patients were divided into the high expression (43 cases) and low expression group (30 cases) according to the expression level of POU6F2-AS2 in the gastric cancer tissues and their corresponding adjacent tissues. The results of the relationship between the expression of POU6F2-AS2 and the clinicopathologic characteristics of patients with gastric cancer showed that the POU6F2-AS2 expression was significantly correlated with the depth of invasion (P=0.022) or the TNM stage (P=0.032). There were no significant differences in the gender, age, smoking history, drinking history, tumor diameter, degree of differentiation, lymph node metastasis, distant metastasis, vascular invasion, nerve invasion, liver metastasis, ascites, and fat nodule metastasis (P>0.050). The overall survival rate of high expression of POU6F2-AS2 in the patient with gastric cancer was significantly worse than that of the low expression of POU6F2-AS2 by the Kaplan Meier Plotter database.Conclusions High expression of POU6F2-AS2 is related to depth of tumor invasion and TNM stage, which indicates that POU6F2-AS2 might play an important role in regulating occurrence and development of gastric cancer. It may be used as an important target for gene diagnosis and treatment of gastric cancer and as a biomarker for evaluating prognosis of patients with gastric cancer.

Citation： YAO Lin, TAN Wang, YANG Facai, XIANG Wanping, XIAO Jiangwei. Expression of long chain noncoding RNA POU6F2-AS2 in human gastric cancer tissues and its clinical significance. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2019, 26(5): 563-567. doi: 10.7507/1007-9424.201812073 Copy

1.	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
2.	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
3.	Van Cutsem E, Sagaert X, Topal B, et al. Gastric cancer. Lancet, 2016, 388(10060): 2654-2664.
4.	Yamaguchi K, Yoshida K, Tanahashi T, et al. The long-term survival of stage Ⅳ gastric cancer patients with conversion therapy. Gastric Cancer, 2018, 21(2): 315-323.
5.	Beermann J, Piccoli MT, Viereck J, et al. Non-coding RNAs in development and disease: background, mechanisms, and therapeutic approaches. Physiol Rev, 2016, 96(4): 1297-1325.
6.	Wu H, Yang L, Chen LL. The diversity of long noncoding RNAs and their generation. Trends Genet, 2017, 33(8): 540-552.
7.	马英博, 张小东, 杨照国, 等. lncRNA 调控肿瘤能量代谢机制的研究进展. 中国普外基础与临床杂志, 2017, 24(3): 381-385.
8.	Sun TT, He J, Liang Q, et al. LncRNA GClnc1 promotes gastric carcinogenesis and may act as a modular scaffold of WDR5 and KAT2A complexes to specify the histone modification pattern. Cancer Discov, 2016, 6(7): 784-801.
9.	Xiao ZD, Han L, Lee H, et al. Energy stress-induced lncRNA FILNC1 represses c-Myc-mediated energy metabolism and inhibits renal tumor development. Nat Commun, 2017, 8(1): 783.
10.	Zhang J, Li Z, Liu L, et al. Long noncoding RNA TSLNC8 is a tumor suppressor that inactivates the interleukin-6/STAT3 signaling pathway. Hepatology, 2018, 67(1): 171-187.
11.	Zhuo W, Liu Y, Li S, et al. Long noncoding RNA GMAN, up-regulated in gastric cancer tissues, is associated with metastasis in patients and promotes translation of Ephrin A1 by competitively binding GMAN-AS. Gastroenterology, 2019, 156(3): 676-691.
12.	张麒, 艾良, 代佑果. 长链非编码 RNA 母系表达基因 3 多态性与胃癌关系的研究. 中国普外基础与临床杂志, 2018, 25(11): 1323-1326.
13.	Washington K. 7th edition of the AJCC cancer staging manual: stomach. Ann Surg Oncol, 2010, 17(12): 3077-3079.
14.	Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol, 2010, 17(6): 1471-1474.
15.	Schefe JH, Lehmann KE, Buschmann IR, et al. Quantitative real-time RT-PCR data analysis: current concepts and the novel " gene expression’s CT difference” formula. J Mol Med (Berl), 2006, 84(11): 901-910.
16.	Huarte M. The emerging role of lncRNAs in cancer. Nat Med, 2015, 21(11): 1253-1261.
17.	Marchese FP, Raimondi I, Huarte M. The multidimensional mechanisms of long noncoding RNA function. Genome Biol, 2017, 18(1): 206.
18.	Kopp F, Mendell JT. Functional classification and experimental dissection of long noncoding RNAs. Cell, 2018, 172(3): 393-407.
19.	Zeng S, Xie X, Xiao YF, et al. Long noncoding RNA LINC00675 enhances phosphorylation of vimentin on Ser83 to suppress gastric cancer progression. Cancer Lett, 2018, 412: 179-187.
20.	Yang XZ, Cheng TT, He QJ, et al. LINC01133 as ceRNA inhibits gastric cancer progression by sponging miR-106a-3p to regulate APC expression and the Wnt/β-catenin pathway. Mol Cancer, 2018, 17(1): 126.
21.	Zhang X, Liang W, Liu J, et al. Long non-coding RNA UFC1 promotes gastric cancer progression by regulating miR-498/Lin28b. J Exp Clin Cancer Res, 2018, 37(1): 134.
22.	Zhao R, Zhang Y, Zhang X, et al. Exosomal long noncoding RNA HOTTIP as potential novel diagnostic and prognostic biomarker test for gastric cancer. Mol Cancer, 2018, 17(1): 68.
23.	Liu J, Sun X, Zhu H, et al. Long noncoding RNA POU6F2-AS2 is associated with oesophageal squamous cell carcinoma. J Biochem, 2016, 160(4): 195-204.
24.	Luo Y, Tan W, Jia W, et al. The long non-coding RNA LINC01606 contributes to the metastasis and invasion of human gastric cancer and is associated with Wnt/β-catenin signaling. Int J Biochem Cell Biol, 2018, 103: 125-134.
25.	Luo Y, Wang C, Yong P, et al. Decreased expression of the long non-coding RNA SLC7A11-AS1 predicts poor prognosis and promotes tumor growth in gastric cancer. Oncotarget, 2017, 8(68): 112530-112549.

1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
2. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
3. Van Cutsem E, Sagaert X, Topal B, et al. Gastric cancer. Lancet, 2016, 388(10060): 2654-2664.
4. Yamaguchi K, Yoshida K, Tanahashi T, et al. The long-term survival of stage Ⅳ gastric cancer patients with conversion therapy. Gastric Cancer, 2018, 21(2): 315-323.
5. Beermann J, Piccoli MT, Viereck J, et al. Non-coding RNAs in development and disease: background, mechanisms, and therapeutic approaches. Physiol Rev, 2016, 96(4): 1297-1325.
6. Wu H, Yang L, Chen LL. The diversity of long noncoding RNAs and their generation. Trends Genet, 2017, 33(8): 540-552.
7. 马英博, 张小东, 杨照国, 等. lncRNA 调控肿瘤能量代谢机制的研究进展. 中国普外基础与临床杂志, 2017, 24(3): 381-385.
8. Sun TT, He J, Liang Q, et al. LncRNA GClnc1 promotes gastric carcinogenesis and may act as a modular scaffold of WDR5 and KAT2A complexes to specify the histone modification pattern. Cancer Discov, 2016, 6(7): 784-801.
9. Xiao ZD, Han L, Lee H, et al. Energy stress-induced lncRNA FILNC1 represses c-Myc-mediated energy metabolism and inhibits renal tumor development. Nat Commun, 2017, 8(1): 783.
10. Zhang J, Li Z, Liu L, et al. Long noncoding RNA TSLNC8 is a tumor suppressor that inactivates the interleukin-6/STAT3 signaling pathway. Hepatology, 2018, 67(1): 171-187.
11. Zhuo W, Liu Y, Li S, et al. Long noncoding RNA GMAN, up-regulated in gastric cancer tissues, is associated with metastasis in patients and promotes translation of Ephrin A1 by competitively binding GMAN-AS. Gastroenterology, 2019, 156(3): 676-691.
12. 张麒, 艾良, 代佑果. 长链非编码 RNA 母系表达基因 3 多态性与胃癌关系的研究. 中国普外基础与临床杂志, 2018, 25(11): 1323-1326.
13. Washington K. 7th edition of the AJCC cancer staging manual: stomach. Ann Surg Oncol, 2010, 17(12): 3077-3079.
14. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol, 2010, 17(6): 1471-1474.
15. Schefe JH, Lehmann KE, Buschmann IR, et al. Quantitative real-time RT-PCR data analysis: current concepts and the novel " gene expression’s CT difference” formula. J Mol Med (Berl), 2006, 84(11): 901-910.
16. Huarte M. The emerging role of lncRNAs in cancer. Nat Med, 2015, 21(11): 1253-1261.
17. Marchese FP, Raimondi I, Huarte M. The multidimensional mechanisms of long noncoding RNA function. Genome Biol, 2017, 18(1): 206.
18. Kopp F, Mendell JT. Functional classification and experimental dissection of long noncoding RNAs. Cell, 2018, 172(3): 393-407.
19. Zeng S, Xie X, Xiao YF, et al. Long noncoding RNA LINC00675 enhances phosphorylation of vimentin on Ser83 to suppress gastric cancer progression. Cancer Lett, 2018, 412: 179-187.
20. Yang XZ, Cheng TT, He QJ, et al. LINC01133 as ceRNA inhibits gastric cancer progression by sponging miR-106a-3p to regulate APC expression and the Wnt/β-catenin pathway. Mol Cancer, 2018, 17(1): 126.
21. Zhang X, Liang W, Liu J, et al. Long non-coding RNA UFC1 promotes gastric cancer progression by regulating miR-498/Lin28b. J Exp Clin Cancer Res, 2018, 37(1): 134.
22. Zhao R, Zhang Y, Zhang X, et al. Exosomal long noncoding RNA HOTTIP as potential novel diagnostic and prognostic biomarker test for gastric cancer. Mol Cancer, 2018, 17(1): 68.
23. Liu J, Sun X, Zhu H, et al. Long noncoding RNA POU6F2-AS2 is associated with oesophageal squamous cell carcinoma. J Biochem, 2016, 160(4): 195-204.
24. Luo Y, Tan W, Jia W, et al. The long non-coding RNA LINC01606 contributes to the metastasis and invasion of human gastric cancer and is associated with Wnt/β-catenin signaling. Int J Biochem Cell Biol, 2018, 103: 125-134.
25. Luo Y, Wang C, Yong P, et al. Decreased expression of the long non-coding RNA SLC7A11-AS1 predicts poor prognosis and promotes tumor growth in gastric cancer. Oncotarget, 2017, 8(68): 112530-112549.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Expression of long chain noncoding RNA POU6F2-AS2 in human gastric cancer tissues and its clinical significance

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content